US EditionPublished • loading... • Updated
Cancer Drug TECVAYLI Slows Disease in Tough-to-Treat Myeloma Patients
TECVAYLI monotherapy showed a 71% reduction in progression or death risk and 40% reduction in death risk in refractory multiple myeloma patients, with manageable safety profile.
- On Jan. 14, 2026, Johnson & Johnson announced MajesTEC-9 topline data showing TECVAYLI monotherapy cut risk of death by 40% versus standard of care.
- MajesTEC-9 enrolled patients with one to three prior lines who all had prior anti-CD38 monoclonal antibody and lenalidomide exposure, targeting those refractory to these agents.
- The study also showed CRS appeared in 95%, with Grade 1 in 50%, Grade 2 in 21%, and Grade 3 in 0.6%, and neurologic toxicity in 57% with ICANS in 6%, serious infections in 30%.
- The study's result positions TECVAYLI as a potential new standard of care, supported by the second positive MajesTEC-9 Phase 3 study and more than 20,800 patients treated since approval.
- Roberto Mina, M.D., commented that 'The MajesTEC-9 results reinforce the potential of TECVAYLI to transform treatment earlier in the multiple myeloma journey', while TECVAYLI remains available only through TALVEY REMS due to CRS and neurologic risks.
Insights by Ground AI
33 Articles
33 Articles
Bennington Banner+29 Reposted by 29 other sources
TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide
TECVAYLI® alone reduced risk of disease progression or death by 71% in a high unmet need population
Coverage Details
Total News Sources33
Leaning Left2Leaning Right2Center11Last UpdatedBias Distribution74% Center
Bias Distribution
- 74% of the sources are Center
74% Center
13%
C 74%
13%
Factuality
To view factuality data please Upgrade to Premium
